To better handle the growth of technologies intended to reduce the need for animal testing for regulatory decisions, a US Food and Drug Administration Science Board subcommittee suggested the agency establish a new central office to oversee so-called new alternative methods (NAMs) in the commissioner’s office.
Key Takeaways
-
A US FDA Science Board report recommends establishing a central office for new alternative methods (NAMs) in the FDA commissioner’s office.
-
Slow adoption of alternatives to animal testing in the current decentralized regulatory framework would benefit from a “one-stop shop” for FDA advice, precedent and qualification programs
The New Alternative Methods Subcommittee presented its
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?